Diet-related complications such as diabetic foot ulcers are the leading cause of death for diabetics. In clinical studies, a wide variety of medications from various pharmacological families are being used to treat diabetic foot ulcers, but only a few have received regulatory approval. Diabetic foot ulcers are caused by a variety of factors, including neuropathy, peripheral artery disease, infection, gender, smoking, and age. Bacterial resistance to present medications is a problem in the treatment of diabetic foot ulcers. For diabetic foot ulcers, this study focuses on the existing treatment, the current treatment method, and potential pharmaceutical targets. Rather of relying on a single medicine to cure a diabetic foot ulcer, a combination of therapy is the best option because several factors contribute to its development. These studies show that treating diabetic foot ulcers in the absence of routine access to laboratory or radiographic testing is possible despite the various challenges that practitioners confront around the world. DFUs are becoming a more important public health problem as they become more prevalent. Because of the difficulty in distinguishing between infection and colonisation in DFU, MDR bacteria have arisen as an issue. In addition, DFU develops biofilms on the skin's outer surface. Biofilm complicates the pathophysiology of DFU and can impede healing. Antibiotic-resistant conditions, such as those caused by biofilm-forming bacteria and MDR bacteria, can lead to chronic wounds, infection, and even lower-limb amputation. In this case, antibiotic alternatives would be very appreciated in the treatment of DFU. Antibiofilm approaches, which can prevent the production of microbial biofilms as well as wound chronicity, are among the creative alternative treatments for the management of DFU wounds that are discussed in this study. DFU can be treated more quickly and effectively if these cutting-edge therapeutic options are used instead of or in conjunction with more established methods.